PR Newswire BiotechOriginal article
Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
RegulatoryapprovedLUMVOAPositive
AI Analysis
Summary
Viridian's LUMVOA has been approved for Graves' ophthalmopathy, driving expected market growth at a 9% CAGR through 2036 as disease awareness and emerging therapies expand treatment options.
Outcome Details
LUMVOA approved for Graves' ophthalmopathy
Importance:6/10
Sentiment:
0.60
Graves' ophthalmopathyautoimmune diseaseFDA approvalmarket expansionLUMVOA
Related Companies
Read the original article
Published by PR Newswire Biotech on July 29, 2026 2:31 PM